GLP-1 receptor agonists: A clinical perspective on cardiovascular effects

The active incretin hormone glucagon-like peptide-1(7-36)amide (GLP-1) is a 30-amino acid peptide that exerts glucoregulatory and insulinotropic actions by functioning as an agonist for the GLP-1 receptor (GLP-1R). In addition to its anti-diabetic effects, GLP-1 has demonstrated cardioprotective act...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes & vascular disease research 2012-04, Vol.9 (2), p.95-108
Main Authors: Mundil, Dhanwantee, Cameron-Vendrig, Alison, Husain, Mansoor
Format: Article
Language:English
Subjects:
Animals
Biomarkers - blood
Blood Glucose - drug effects
Blood Glucose - metabolism
Cardiovascular Diseases - chemically induced
Cardiovascular Diseases - mortality
Cardiovascular Diseases - prevention & control
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - mortality
Drug Design
Evidence-Based Medicine
Glucagon-Like Peptide 1 - adverse effects
Glucagon-Like Peptide 1 - analogs & derivatives
Glucagon-Like Peptide 1 - therapeutic use
Glucagon-Like Peptide-1 Receptor
Glycated Hemoglobin A - metabolism
Humans
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Liraglutide
Peptides - adverse effects
Peptides - therapeutic use
Receptors, Glucagon - agonists
Receptors, Glucagon - metabolism
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Venoms - adverse effects
Venoms - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The active incretin hormone glucagon-like peptide-1(7-36)amide (GLP-1) is a 30-amino acid peptide that exerts glucoregulatory and insulinotropic actions by functioning as an agonist for the GLP-1 receptor (GLP-1R). In addition to its anti-diabetic effects, GLP-1 has demonstrated cardioprotective actions. Here we review the cardiovascular effects of the GLP-1 analogues currently approved for the treatment of type 2 diabetes, namely exenatide and liraglutide. We discuss their anti-hyperglycaemic efficacy, and offer a clinical perspective of their effects on cardiovascular risk factors such as body weight, blood pressure, heart rate and lipid profiles, as well as their potential consequences on cardiovascular events, such as arrhythmias, heart failure, myocardial infarction and death. Lastly, we briefly review additional GLP-1R agonists in clinical development.
ISSN:1479-1641
1752-8984
DOI:10.1177/1479164112441526